Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 7Lymphoma, T-Cell 3Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

Doxorubicin 8Vincristine 7Prednisone 7Cyclophosphamide 7Rituximab 5VAP-cyclo protocol 3Radiotherapy 3Methotrexate 3Filgrastim 3Cytarabine 3liposomal amphotericin B 2Vinblastine 2Levofloxacin 2Leucovorin 2Hydrocortisone 2Etoposide 2Early Intervention, Educational 2Drug Therapy 2Dexamethasone 2Darbepoetin alfa 2liposomal doxorubicin 1ferrous sulfate 1ferric gluconate 1belinostat 1Sucrose 1Steroids 1Stem Cell Transplantation 1Standard of Care 1Specimen Handling 1Psychiatric Rehabilitation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, Large-Cell, Anaplastic × 10-propargyl-10-deazaaminopterin × Clear all
NCT06561048 2026-04-08

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Corvus Pharmaceuticals, Inc.

Phase 3 Recruiting
150 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡